BioLife Solutions financials
$39.22+0.18%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $96.2M | $74.6M | $68.0M | $76.2M | $119.2M | $48.1M | $27.4M | $19.7M | $11.0M | $8.2M |
| Gross profit | $62.1M | $50.1M | $41.3M | $46.9M | $37.0M | $27.4M | $18.6M | $13.5M | $6.7M | $4.8M |
| Gross margin | 64.6% | 67.1% | 60.7% | 61.5% | 31.1% | 57.1% | 68.0% | 68.5% | 61.2% | 58.1% |
| Operating income | -$16.6M | -$4.5M | -$17.2M | -$5.9M | -$33.5M | -$4.7M | -$170.0K | $3.7M | -$1.1M | -$7.6M |
| Net income | -$4.6M | -$20.2M | -$68.0M | -$139.8M | -$8.9M | $1.8M | -$1.7M | -$25.3M | -$2.7M | -$6.9M |
| Net margin | −4.8% | −27.0% | −100.0% | −183.4% | −7.5% | 3.8% | −6.1% | −128.4% | −24.8% | −83.6% |
| Diluted EPS | $-0.10 | $-0.44 | $-1.55 | $-3.25 | $-0.23 | $-0.06 | $-0.09 | $-1.56 | $-0.21 | $-0.54 |
| EBITDA | -$11.9M | $4.2M | -$4.9M | $5.8M | -$17.8M | $1.1M | $2.6M | $4.0M | -$844.0K | -$4.5M |
| Operating cash flow | $20.1M | $8.4M | -$12.5M | -$8.5M | -$4.6M | $6.6M | $1.2M | $2.3M | $605.0K | -$4.3M |
| Free cash flow | $9.8M | $3.1M | -$23.7M | -$22.4M | -$19.3M | $2.0M | $538.0K | $1.8M | $461.0K | -$4.5M |
| Diluted shares | 48.6M | 46.1M | 43.7M | 43.1M | 38.5M | 27.3M | 19.5M | 16.3M | 13.3M | 12.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.0M | $91.5M | $27.9M | $19.4M | $69.9M | $90.4M |
| Short-term investments | $55.9M | $9.2M | $16.3M | $43.3M | $0.00 | — |
| Total debt | $5.0M | $15.9M | $23.8M | $25.9M | $7.7M | $1.3M |
| Total assets | $405.9M | $399.5M | $412.7M | $450.2M | $554.3M | $234.8M |
| Total liabilities | $34.0M | $50.6M | $75.1M | $86.0M | $76.2M | $29.6M |
| Shareholders' equity | $371.9M | $348.9M | $337.7M | $364.2M | $478.0M | $205.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology